Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


STOCKWATCH: Roche's old school scheme traps investors in young Puma

This article was originally published in Scrip

Executive Summary

There are some good old school tricks in pharmaceutical development, like publishing patents for sub-optimal compounds to send your competitors off into unproductive areas of chemical space. These tricks aren't written down anywhere (apart from that one) but are stored in the collective experience of old heads in the pharma jungle. Sometimes young cubs in biotechnology who don't know the old ways tricks fall straight into the traps that they could have avoided. This is what seems to have to Puma Biotechnology, the 'trendingest' entity in biotech last week.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts